A case report suggests ashwagandha may rarely trigger extreme sleepiness, unusual sleep behaviors, and short-term confusion—even at common doses.
A case report suggests ashwagandha may rarely trigger extreme sleepiness, unusual sleep behaviors, and short-term confusion—even at common doses.
Researchers described a single patient who developed sudden confusion and unusual sleep-related behavior soon after taking an ashwagandha supplement (an herb often marketed for stress and sleep). The man took one 250 mg tablet one day, then increased to two tablets (500 mg) the next day. Within hours, he slept for about 23 hours and had odd movements and behaviors during sleep, followed by grogginess, disorientation, and memory gaps when he finally woke up.
In the hospital, doctors ran extensive tests to look for dangerous causes like stroke, brain infection, metabolic problems (such as abnormal salts or thyroid issues), or autoimmune disease. Brain scans (CT and MRI) were normal, and spinal fluid tests did not show infection. His symptoms improved after stopping ashwagandha and fully resolved within three days.
For seniors, this matters because many people use herbal supplements without medical supervision, and older adults may be more sensitive to sedating effects or interactions with other medicines. This report is a reminder that “natural” does not always mean risk-free.
Use the full description to understand the study design, methods, and the limits of the findings.
This article is based on a detailed medical case report describing a possible rare side effect linked to ashwagandha.
Study design (in simple terms): A single-person case report. Doctors documented symptoms, timing, testing, and recovery after stopping the supplement.
Key findings (with numbers): Symptoms began a few hours after taking two tablets (total 500 mg). The patient slept about 23 hours and arrived confused with a 4AT delirium screening score of 10 (a high score). CT and MRI brain scans were normal. Spinal fluid testing for infections (including HSV and VZV) was negative. He improved within hours and returned to baseline by day 3. A causality tool (Naranjo scale) scored the reaction as 7 = “probable”.
Limitations/caveats: This is only one case, so it cannot tell us how often this happens or who is most at risk. The supplement brand and purity can vary, and an EEG (a brain-wave test) was not done. Case reports can suggest a warning signal but do not prove cause for everyone.
Practical implications for daily life: If you take ashwagandha, be cautious with dose increases, and watch for excessive sleepiness, vivid/strange dreams, confusion, unsteady walking, or unusual nighttime behaviors. Avoid mixing supplements with sedating medications or alcohol unless your clinician says it’s safe. If sudden confusion occurs, treat it as urgent and seek medical care.
Bring a full list of all supplements (including “natural” products) to your healthcare provider or pharmacist, especially if you take medicines for blood pressure, mood, sleep, or pain.
Open the original publication for the complete methods, outcomes, and source material.
Methodologically, this is low-level evidence (a single-person case report). Its main value is as a safety signal: it documents a plausible time-linked adverse event with a reasonably thorough clinical evaluation and symptom resolution after stopping the supplement (dechallenge), plus a structured causality assessment (Naranjo). However, it cannot establish causation, quantify risk, or rule out all confounders. For adults 60+, the topic is highly relevant (delirium risk, polypharmacy, supplement variability), but the evidence strength remains limited because conclusions rest on one case and product composition/contaminants may be uncertain without independent verification.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 2.5/10 | |
| Bias & Methods | 4.0/10 | |
| Statistical Integrity | 1.0/10 | |
| Transparency | 6.5/10 | |
| Conflict of Interest Disclosure | 5.0/10 | |
| Replication / External Validation | 2.0/10 | |
| Relevance to Seniors | 6.0/10 | |
| Journal Quality | 6.0/10 |
Conservative interpretation is warranted: case reports are prone to publication bias (unusual events are more likely to be reported) and cannot determine frequency or identify who is at risk. Product variability is a major limitation for supplement-related reports; ideally, the exact formulation, batch/lot, and independent testing would be documented. If the full text includes explicit age, comorbidities, concomitant medications (especially sedatives/anticholinergics), and formal COI/funding statements, relevance and conflicts scores could be adjusted accordingly.
These condition pages help connect the paper back to the real-world health concerns it addresses.
Review the interventions studied here and compare them against the broader treatment library.
Build a personalized plan using research-backed studies, conditions, and treatments.